Retrospective non–randomized study of 36 eyes of type–2 diabetes patients with persistent diabetic macular edema, who received single intravitreal bevacizumab with follow up for six months without any further intervention. Primary outcome measure was the change in central macular thickness(CMT). Secondary outcome measure was the change in best corrected visual acuity(BCVA). Baseline mean CMT was 534.93±110.48 µ. Mean CMT at month six was 359.1 ± 109.3 µ, the change being significant (p=0.03). Decrease in mean CMT at all the follow ups was significant as compared to baseline.  Rebound was observed at month four, five and six. At month four, 20(55.6%) eyes had rebound edema compared to month three. Significant improvement in BCVA was noted at each follow up compared to baseline (1.58 ± 0.27). Single intravitreal bevacizumab was effective in improvement in BCVA and reduction of macular edema for six month period with rebound of edema from month three.